> Schering-Plough will develop a compound identified by Pharmacopeia as part of the companies' ongoing collaboration, triggering milestone payments for Pharmacopeia. The compound is being evaluated as a potential treatment for respiratory disease. Release
> Epsilon Pharmaceuticals has acquired the shares of Cellegy Australia in exchange for $1.25 million in cash. Release
> Chiron has initiated a Phase I trial for CHIR-265 in melanoma. Release
> The FDA has ruled out RU-486 in one of two deaths in women who had taken the drug and subsequently contracted a rare infection. Report
> Consumer advocacy organization Public Citizen wants GlaxoSmithKline's Xenical removed from the market, saying that the drug's risks outweigh its benefits. Report
> Some researchers are accusing drug companies of "disease mongering," a tactic that raises awareness of non-existent diseases or exaggerates mild problems to boost profits. Article
And Finally... If you're afraid of needles, help may be on the way. A "nanopatch" in development could render injections obsolete. Article